Next Article in Journal
Presence of the Human Cytomegalovirus in Glioblastomas—A Systematic Review
Previous Article in Journal
Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors
Previous Article in Special Issue
Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?
Article

Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis

1
Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria
2
Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria
3
Department of Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, 1090 Vienna, Austria
4
Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Academic Editors: Caroline Gronnier and Denis Collet
Cancers 2021, 13(20), 5050; https://doi.org/10.3390/cancers13205050
Received: 20 September 2021 / Revised: 30 September 2021 / Accepted: 6 October 2021 / Published: 9 October 2021
(This article belongs to the Special Issue New Trends in Esophageal Cancer Management)
Thyroid hormones are surmised to be associated with cancer. However, so far, there is no sufficient data on the association of thyroid hormone status as well as replacement therapy in patients with upper gastrointestinal cancer Thus, we analyzed clinical as well as endocrinological parameters of 865 patients with resectable gastroesophageal cancer treated at the Medical University of Vienna, which is a large representative European cohort. A tendency towards prolonged overall survival in hypothyroid patients (euthyroid, n = 647: median OS 29.7 months; hyperthyroid, n = 50: 23.1 months; hypothyroid, n = 70: 47.9 months; p = 0.069) as well as a significant positive correlation of thyroid hormone replacement therapy with the overall survival was observed (without, n = 53: median OS 30.6 months; with, n = 67: 51.3 months; p = 0.017). Thus, thyroid disorders and their therapeutic interventions might pose as potential prognostic tools and further prospective analyses are warranted.
Introduction: As thyroid hormones modulate proliferative pathways it is surmised that they can be associated with cancer development. Since the potential association of gastroesophageal cancer and thyroid disorders has not been addressed so far, the aim of this study was to investigate the association of thyroid hormone parameters with the outcome of these patients, so novel prognostic and even potentially therapeutic markers can be defined. Material and Methods: Clinical and endocrinological parameters of patients with resectable gastroesophageal cancer treated between 1990 and 2018 at the Vienna General Hospital, Austria, including history of endocrinological disorders and laboratory analyses of thyroid hormones at first cancer diagnosis were investigated and correlated with the overall survival (OS). Results: In a total of 865 patients, a tendency towards prolonged OS in hypothyroid patients (euthyroid, n = 647: median OS 29.7 months; hyperthyroid, n = 50: 23.1 months; hypothyroid, n = 70: 47.9 months; p = 0.069) as well as a significant positive correlation of thyroid hormone replacement therapy with the OS was observed (without, n = 53: median OS 30.6 months; with, n = 67: 51.3 months; p = 0.017). Furthermore, triiodothyronine (T3) levels were also associated with the OS (median OS within the limit of normal: 23.4, above: 32.4, below: 9.6 months; p = 0.045). Conclusions: Thyroid disorders and their therapeutic interventions might be associated with the OS in patients with resectable gastroesophageal cancer. As data on the correlation of these parameters is scarce, this study proposes an important impulse for further analyses concerning the association of thyroid hormones with the outcome in patients with gastroesophageal tumors. View Full-Text
Keywords: gastrointestinal neoplasms; stomach neoplasms; esophageal neoplasms; thyroid gland; thyroid diseases gastrointestinal neoplasms; stomach neoplasms; esophageal neoplasms; thyroid gland; thyroid diseases
Show Figures

Figure 1

MDPI and ACS Style

Puhr, H.C.; Reiter, T.J.; El-Mahrouk, M.; Saliternig, L.; Wolf, P.; Mair, M.J.; Steindl, A.; Paireder, M.; Asari, R.; Schoppmann, S.F.; Berghoff, A.S.; Preusser, M.; Ilhan-Mutlu, A. Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis. Cancers 2021, 13, 5050. https://doi.org/10.3390/cancers13205050

AMA Style

Puhr HC, Reiter TJ, El-Mahrouk M, Saliternig L, Wolf P, Mair MJ, Steindl A, Paireder M, Asari R, Schoppmann SF, Berghoff AS, Preusser M, Ilhan-Mutlu A. Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis. Cancers. 2021; 13(20):5050. https://doi.org/10.3390/cancers13205050

Chicago/Turabian Style

Puhr, Hannah C., Thorsten J. Reiter, Mohamed El-Mahrouk, Lena Saliternig, Peter Wolf, Maximilian J. Mair, Ariane Steindl, Matthias Paireder, Reza Asari, Sebastian F. Schoppmann, Anna S. Berghoff, Matthias Preusser, and Aysegül Ilhan-Mutlu. 2021. "Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis" Cancers 13, no. 20: 5050. https://doi.org/10.3390/cancers13205050

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop